Edwards Lifesciences Corporation (EW) has underperformed the broader S&P 500 Index over the past year, though it has outpaced the iShares U.S. Medical Devices ETF. Analysts have a “Moderate Buy” consensus rating for EW, with an average price target indicating a significant upside from current levels. The company reported strong Q3 results, exceeding revenue expectations and meeting EPS forecasts.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Palmetto Grain Brokerage - What Are Wall Street Analysts' Target Price for Edwards Lifesciences Stock?
Edwards Lifesciences Corporation (EW) has underperformed the broader S&P 500 Index over the past year, though it has outpaced the iShares U.S. Medical Devices ETF. Analysts have a “Moderate Buy” consensus rating for EW, with an average price target indicating a significant upside from current levels. The company reported strong Q3 results, exceeding revenue expectations and meeting EPS forecasts.